These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28025011)

  • 21. Transient increment of HTLV-2 proviral load in HIV-1-co-infected patients during treatment intensification with raltegravir.
    Abad-Fernández M; Cabrera C; García E; Vallejo A
    J Clin Virol; 2014 Mar; 59(3):204-7. PubMed ID: 24457115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice.
    Jaeckle M; Khaykin P; Haberl A; De Leuw P; Schüttfort G; Stephan C; Wolf T
    Int J STD AIDS; 2016 Nov; 27(13):1170-1179. PubMed ID: 26429890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.
    Stephan C; Baldauf HM; Barry J; Giordano FA; Bartholomae CC; Haberl A; Bickel M; Schmidt M; Laufs S; Kaderali L; Keppler OT
    J Antimicrob Chemother; 2014 Oct; 69(10):2809-18. PubMed ID: 24962031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
    Reigadas S; Andréola ML; Wittkop L; Cosnefroy O; Anies G; Recordon-Pinson P; Thiébaut R; Masquelier B; Fleury H
    J Antimicrob Chemother; 2010 Mar; 65(3):434-7. PubMed ID: 20051476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five years' real-life experience with raltegravir in a large HIV centre.
    van Halsema C; Whitfield T; Lin N; Ashton K; Torkington A; Ustianowski A
    Int J STD AIDS; 2016 Apr; 27(5):387-93. PubMed ID: 25931236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
    Vallejo A; Gutierrez C; Hernandez-Novoa B; Diaz L; Madrid N; Abad-Fernandez M; Dronda F; Perez-Elias MJ; Zamora J; Muñoz E; Muñoz-Fernandez MA; Moreno S
    AIDS; 2012 Sep; 26(15):1885-94. PubMed ID: 22992577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of antiretroviral regimens including raltegravir to treat HIV-infected patients with hemophilia.
    Xiao H; Xue Y; Gu S; Wang J; Sun H; Lu H
    Biosci Trends; 2016 Feb; 10(1):42-6. PubMed ID: 26911541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV dynamics linked to memory CD4+ T cell homeostasis.
    Murray JM; Zaunders J; Emery S; Cooper DA; Hey-Nguyen WJ; Koelsch KK; Kelleher AD
    PLoS One; 2017; 12(10):e0186101. PubMed ID: 29049331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.
    Hatano H; Scherzer R; Wu Y; Harvill K; Maka K; Hoh R; Sinclair E; Palmer S; Martin JN; Busch MP; Deeks SG; Hsue PY
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):317-25. PubMed ID: 22918156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
    Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
    Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals.
    Massanella M; Ouchi D; Marfil S; Llibre JM; Puertas MC; Buzón MJ; Richman DD; Orna E; Stevenson M; Gatell JM; Domingo P; Negredo E; Martinez-Picado J; Clotet B; Blanco J
    PLoS One; 2014; 9(12):e114142. PubMed ID: 25462535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
    Buzón MJ; Codoñer FM; Frost SD; Pou C; Puertas MC; Massanella M; Dalmau J; Llibre JM; Stevenson M; Blanco J; Clotet B; Paredes R; Martinez-Picado J
    PLoS Pathog; 2011 Oct; 7(10):e1002314. PubMed ID: 22046128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir.
    Flandre P; Marcelin AG; Calvez V;
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):448-454. PubMed ID: 28653971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
    Nicastri E; Tommasi C; Abbate I; Bonora S; Tempestilli M; Bellagamba R; Viscione M; Rozera G; Gallo AL; Ivanovic J; Amendola A; Pucillo L; Di Perri G; Capobianchi MR; Narciso P
    Antivir Ther; 2011; 16(6):797-803. PubMed ID: 21900711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
    Massanella M; Negredo E; Puig J; Puertas MC; Buzón MJ; Pérez-Álvarez N; Carrillo J; Clotet B; Martínez-Picado J; Blanco J
    AIDS; 2012 Nov; 26(18):2285-93. PubMed ID: 23018435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
    Murray JM; Emery S; Kelleher AD; Law M; Chen J; Hazuda DJ; Nguyen BY; Teppler H; Cooper DA
    AIDS; 2007 Nov; 21(17):2315-21. PubMed ID: 18090280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.